p53 N-terminal phosphorylation: A defining layer of complex regulation

Carcinogenesis

Volumn 33, Issue 8, 2012, Pages 1441-1449

  Jenkins, Lisa M Miller ^a   Durell, Stewart R ^a   Mazur, Sharlyn J ^a   Appella, Ettore ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; CELL METABOLISM; GENE MUTATION; GENOTYPE; HUMAN; HYDROPHOBICITY; IN VIVO STUDY; MOLECULAR MODEL; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; TRANSACTIVATION;

ANIMALS; HUMANS; MICE; MODELS, MOLECULAR; PHOSPHORYLATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84865310407     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs145     Document Type: Review

References (88)

1. Beckerman, R. et al. (2010) Transcriptional regulation by p53. Cold Spring Harb. Perspect. Biol., 2, a000935.
2. Petitjean, A. et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat., 28, 622-629.
3. Goh, A.M. et al. (2011) The role of mutant p53 in human cancer. J. Pathol., 223, 116-126.
4. Woods, D.B. et al. (2001) Regulation of p53 function. Exp. Cell Res., 264, 56-66.
5. El-Deiry, W.S. et al. (1992) Definition of a consensus binding site for p53. Nat. Genet., 1, 45-49.
6. Anderson, C.W. et al. (2009) Signaling to the p53 tumor suppressor through pathways activated by genotoxic and non-genotoxic stresses. In Bradshaw, R.A. and Dennis, E.A. (eds) Handbook of Cell Signaling. Elsevier, Amsterdam, The Netherlands, pp. 2185-2203.
7. Meek, D.W. et al. (2009) Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb. Perspect. Biol., 1, a000950.
8. Yakovlev, V.A. et al. (2010) Nitration of the tumor suppressor protein p53 at tyrosine 327 promotes p53 oligomerization and activation. Biochemistry, 49, 5331-5339.
9. Chuikov, S. et al. (2004) Regulation of p53 activity through lysine methylation. Nature, 432, 353-360.
10. Huang, J. et al. (2006) Repression of p53 activity by Smyd2-mediated methylation. Nature, 444, 629-632.
11. Xirodimas, D.P. et al. (2004) Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell, 118, 83-97.
12. Chan, W.M. et al. (2006) Ubiquitination of p53 at multiple sites in the DNA-binding domain. Mol. Cancer Res., 4, 15-25.
13. Rodriguez, M.S. et al. (2000) Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol. Cell. Biol., 20, 8458-8467.
14. Ohki, R. et al. (2007) Dissecting functional roles of p53 N-terminal transactivation domains by microarray expression analysis. Cancer Sci., 98, 189-200.
15. Berger, S.L. (2010) Keeping p53 in check: a high-stakes balancing act. Cell, 142, 17-19.
16. Brooks, C.L. et al. (2011) The impact of acetylation and deacetylation on the p53 pathway. Protein Cell, 2, 456-462.
17. Dai, C. et al. (2010) p53 post-translational modification: deregulated in tumorigenesis. Trends Mol. Med., 16, 528-536.
18. Brooks, C.L. et al. (2011) p53 regulation by ubiquitin. FEBS Lett., 585, 2803-2809.
19. Hock, A. et al. (2010) Regulation of the p53 pathway by ubiquitin and related proteins. Int. J. Biochem. Cell Biol., 42, 1618-1621.
20. Cai, X. et al. (2008) Inhibition of Thr-55 phosphorylation restores p53 nuclear localization and sensitizes cancer cells to DNA damage. Proc. Natl Acad. Sci. USA, 105, 16958-16963.
21. Pavithra, L. et al. (2009) SMAR1 forms a ternary complex with p53-MDM2 and negatively regulates p53-mediated transcription. J. Mol. Biol., 388, 691-702.
22. Cordenonsi, M. et al. (2007) Integration of TGF-beta and Ras/MAPK signaling through p53 phosphorylation. Science, 315, 840-843.
23. Armata, H.L. et al. (2007) The ataxia telangiectasia-mutated target site Ser18 is required for p53-mediated tumor suppression. Cancer Res., 67, 11696-11703.
24. Armata, H.L. et al. (2010) Requirement of the ATM/p53 tumor suppressor pathway for glucose homeostasis. Mol. Cell. Biol., 30, 5787-5794.
25. Armata, H.L. et al. (2011) Loss of p53 Ser18 and Atm results in embryonic lethality without cooperation in tumorigenesis. PLoS One, 6, e24813.
26. Chao, C. et al. (2003) Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses. J. Biol. Chem., 278, 41028-41033.
27. Chao, C. et al. (2006) Ser18 and 23 phosphorylation is required for p53-dependent apoptosis and tumor suppression. EMBO J., 25, 2615-2622.
28. MacPherson, D. et al. (2004) Defective apoptosis and B-cell lymphomas in mice with p53 point mutation at Ser 23. EMBO J., 23, 3689-3699.
29. Sluss, H.K. et al. (2004) Phosphorylation of serine 18 regulates distinct p53 functions in mice. Mol. Cell. Biol., 24, 976-984.
30. Feng, L. et al. (2006) Ser46 phosphorylation regulates p53-dependent apoptosis and replicative senescence. Cell Cycle, 5, 2812-2819.
31. Johnson, T.M. et al. (2005) The p53QS transactivation-deficient mutant shows stress-specific apoptotic activity and induces embryonic lethality. Nat. Genet., 37, 145-152.
32. Brady, C.A. et al. (2011) Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell, 145, 571-583.
33. Gaidarenko, O. et al. (2009) Transcription activity is required for p53-dependent tumor suppression. Oncogene, 28, 4397-4401.
34. Johnson, T.M. et al. (2005) p53QS: an old mutant teaches us new tricks. Cell Cycle, 4, 731-734.
35. Liu, D. et al. (2010) Puma is required for p53-induced depletion of adult stem cells. Nat. Cell Biol., 12, 993-998.
36. Wang, P.Y. et al. (2012) p53: exercise capacity and metabolism. Curr. Opin. Oncol., 24, 76-82.
37. Donehower, L.A. et al. (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature, 356, 215-221.
38. Vise, P. et al. (2007) Identifying long-range structure in the intrinsically unstructured transactivation domain of p53. Proteins, 67, 526-530.
39. Gsponer, J. et al. (2009) The rules of disorder or why disorder rules. Prog. Biophys. Mol. Biol., 99, 94-103.
40. Oldfield, C.J. et al. (2008) Flexible nets: disorder and induced fit in the associations of p53 and 14-3-3 with their partners. BMC Genomics, 9 (suppl. 1), S1.
41. Daughdrill, G.W. et al. (2012) Understanding the structural ensembles of a highly extended disordered protein. Mol. Biosyst., 8, 308-319.
42. Hazy, E. et al. (2009) Limitations of induced folding in molecular recognition by intrinsically disordered proteins. Chemphyschem, 10, 1415-1419.
43. Kussie, P.H. et al. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science, 274, 948-953.
44. Popowicz, G.M. et al. (2008) Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle, 7, 2441-2443.
45. Popowicz, G.M. et al. (2007) Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle, 6, 2386-2392.
46. Barlev, N.A. et al. (2001) Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Mol. Cell, 8, 1243- 1254.
47. Liu, G. et al. (2003) The activation domains, the proline-rich domain, and the C-terminal basic domain in p53 are necessary for acetylation of histones on the proximal p21 promoter and interaction with p300/CREB-binding protein. J. Biol. Chem., 278, 17557-17565.
48. Espinosa, J.M. et al. (2001) Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol. Cell, 8, 57-69.
49. Hsu, C.H. et al. (2004) HCMV IE2-mediated inhibition of HAT activity downregulates p53 function. EMBO J., 23, 2269-2280.
50. Luo, J. et al. (2001) Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell, 107, 137-148.
51. Vaziri, H. et al. (2001) hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell, 107, 149-159.
52. Avantaggiati, M.L. et al. (1997) Recruitment of p300/CBP in p53-dependent signal pathways. Cell, 89, 1175-1184.
53. Scolnick, D.M. et al. (1997) CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res., 57, 3693-3696.
54. Dornan, D. et al. (2003) DNA-dependent acetylation of p53 by the transcription coactivator p300. J. Biol. Chem., 278, 13431-13441.
55. Grossman, S.R. et al. (1998) p300/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol. Cell, 2, 405-415.
56. Gu, W. et al. (1997) Synergistic activation of transcription by CBP and p53. Nature, 387, 819-823.
57. Livengood, J.A. et al. (2002) p53 Transcriptional activity is mediated through the SRC1-interacting domain of CBP/p300. J. Biol. Chem., 277, 9054-9061.
58. Van Orden, K. et al. (1999) Binding of p53 to the KIX domain of CREB binding protein. A potential link to human T-cell leukemia virus, type Iassociated leukemogenesis. J. Biol. Chem., 274, 26321-26328.
59. Teufel, D.P. et al. (2007) Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53. Proc. Natl Acad. Sci. USA, 104, 7009-7014.
60. Lee, C.W. et al. (2010) Graded enhancement of p53 binding to CREBbinding protein (CBP) by multisite phosphorylation. Proc. Natl Acad. Sci. USA, 107, 19290-19295.
61. Ferreon, J.C. et al. (2009) Cooperative regulation of p53 by modulation of ternary complex formation with CBP/p300 and HDM2. Proc. Natl Acad. Sci. USA, 106, 6591-6596.
62. Teufel, D.P. et al. (2009) Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2. Oncogene, 28, 2112-2118.
63. Jenkins, L.M. et al. (2009) Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylation. Biochemistry, 48, 1244-1255.
64. Polley, S. et al. (2008) Differential recognition of phosphorylated transactivation domains of p53 by different p300 domains. J. Mol. Biol., 376, 8-12.
65. Feng, H. et al. (2009) Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation. Structure, 17, 202-210.
66. Lee, C.W. et al. (2009) Mapping the interactions of the p53 transactivation domain with the KIX domain of CBP. Biochemistry, 48, 2115-2124.
67. Lee, C.W. et al. (2010) Structure of the p53 transactivation domain in complex with the nuclear receptor coactivator binding domain of CREB binding protein. Biochemistry, 49, 9964-9971.
68. Blau, J. et al. (1996) Three functional classes of transcriptional activation domain. Mol. Cell. Biol., 16, 2044-2055.
69. Bochkareva, E. et al. (2005) Single-stranded DNA mimicry in the p53 transactivation domain interaction with replication protein A. Proc. Natl Acad. Sci. USA, 102, 15412-15417.
70. Rajagopalan, S. et al. (2010) Mapping the physical and functional interactions between the tumor suppressors p53 and BRCA2. Proc. Natl Acad. Sci. USA, 107, 8587-8592.
71. Wong, T.S. et al. (2009) Physical and functional interactions between human mitochondrial single-stranded DNA-binding protein and tumour suppressor p53. Nucleic Acids Res., 37, 568-581.
72. Debnath, S. et al. (2011) Peptide-protein interactions suggest that acetylation of lysines 381 and 382 of p53 is important for positive coactivator 4-p53 interaction. J. Biol. Chem., 286, 25076-25087.
73. Rajagopalan, S. et al. (2009) Interaction between the transactivation domain of p53 and PC4 exemplifies acidic activation domains as single-stranded DNA mimics. J. Biol. Chem., 284, 21728-21737.
74. Al Rashid, S.T. et al. (2011) Protein-protein interactions occur between p53 phosphoforms and ATM and 53BP1 at sites of exogenous DNA damage. Radiat. Res., 175, 588-598.
75. Brown, C.J. et al. (2008) The electrostatic surface of MDM2 modulates the specificity of its interaction with phosphorylated and unphosphorylated p53 peptides. Cell Cycle, 7, 608-610.
76. Lee, H.J. et al. (2007) Modulation of the p53-MDM2 interaction by phosphorylation of Thr18: a computational study. Cell Cycle, 6, 2604-2611.
77. Shouse, G.P. et al. (2008) Serine 15 phosphorylation of p53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma-specific protein phosphatase 2A. Mol. Cell. Biol., 28, 448- 456.
78. Di Lello, P. et al. (2006) Structure of the Tfb1/p53 complex: insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53. Mol. Cell, 22, 731-740.
79. Abramova, N.A. et al. (1997) Interaction between replication protein A and p53 is disrupted after UV damage in a DNA repair-dependent manner. Proc. Natl Acad. Sci. USA, 94, 7186-7191.
80. Saito, S. et al. (2003) Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J. Biol. Chem., 278, 37536-37544.
81. Bourougaa, K. et al. (2010) Endoplasmic reticulum stress induces G2 cell-cycle arrest via mRNA translation of the p53 isoform p53/47. Mol. Cell, 38, 78-88.
82. Melis, J.P. et al. (2011) Genotoxic exposure: novel cause of selection for a functional DeltaN-p53 isoform. Oncogene, 30, 1764-1772.
83. Ungewitter, E. et al. (2010) Delta40p53 controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCs. Genes Dev., 24, 2408-2419.
84. Smeenk, L. et al. (2011) Role of p53 serine 46 in p53 target gene regulation. PLoS One, 6, e17574.
85. Kumamoto, K. et al. (2008) Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res., 68, 3193-3203.
86. Thompson, T. et al. (2004) Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J. Biol. Chem., 279, 53015-53022.
87. Lin, J.Y. et al. (2004) Association of Ubc9, an E2 ligase for SUMO conjugation, with p53 is regulated by phosphorylation of p53. FEBS Lett., 573, 15-18.
88. Ozeki, C. et al. (2011) Cancer susceptibility polymorphism of p53 at codon 72 affects phosphorylation and degradation of p53 protein. J. Biol. Chem., 286, 18251-18260.